Wayinia Lifesciences is an exclusive marketing partner for Glycosorb®-ABO in India.

Glycosorb®-ABO enables organ transplants across the blood group boundaries in a patient-friendly and safe manner. The product has been used successfully at approximately 2000 transplants. Several independent studies from different countries show that the results of blood-group-compatible kidney transplants are also excellent over a longer follow-up period and are equivalent to the results of blood-group-compatible transplants.


Specific

The absolute benefit of Glycosorb®-ABO is that it does not significantly affect other antibodies or blood proteins, making it the only product of its kind in the market.

Patient benefit

With the help of Glycosorb®-ABO, you circumvent the blood group barrier, which results in more patients being able to undergo transplantation and reducing waiting times. A transplant provides a higher expected life expectancy and an improvement in the patient's quality of life.

Utilities

Transplanting a patient instead of continued dialysis treatment results in major cost savings for the healthcare industry. With a dialysis population in Europe and the United States reaching almost one million patients and increasing (about 6-8 percent a year in the United States) there is a great need for more transplants. Even the possibility of transplanting other organs increases.

Logistics

The use of Glycosorb®-ABO makes it more possible to match organs between sensors and recipients. As a result, more patients can be transplanted and the waiting time for many patients can be reduced. Paired exchange is considered by many to be logistically complicated, costly and can lead to extended waiting times for patients with an ABO incompatible sensor compared to using Glycosorb®-ABO. Therefore, Paired Exchange could instead focus more on matching HLA incompatible (sensitized) patients.


Below is a selection of medical publications that treat Glycosorb ® -ABO

Function and biocompatibility

Rydberg L, Bengtsson A, Samuelsson O, Nilsson K, Breimer ME 
In Vitro Assessment of Glycosorb® ABO A New ABO Immunosorbent With Synthetic Carbohydrates Attached To Sepharose
Transpl Int. 2005, 17 (11): 666-72. Epub 2004 Nov 17

http://onlinelibrary.wiley.com/doi/10.1111/j.1432-2277.2004.tb00492.x/abstract

Kidney

Tydén G, Kumlien G, Fehrman
Successful ABO-incompatible kidney transplants without splenectomy using antigen-specific immunoadsorption and rituximab
Transplantation 2003; 76 (4): 730-731
http://www.ncbi.nlm.nih.gov/pubmed/12973118
Wilpert J, Fischer KG, Pisarski P, Wiech T, Daskalakis M, Ziegler A, Neumann-Haefelin E, Drognitz O, Emmerich F, Walz G, Geyer


M; Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis
Nephrol Dial Transplant 2010; 25 (11): 3778-86
http://www.ncbi.nlm.nih.gov/pubmed/20466677
Tydén G, Kumlien G, Berg B


ABO-incompatible kidney transplant in children Pediatric
Transplant 2011; 15 (5): 502-4 
http://www.researchgate.net/publication/51504135_ABO-incompatible_kidney_transplantation_in_children
Tijdén G, Donauer J, Wadström J, Kumlien G, Wilpert J, Nilsson T, Genberg H, Pisarki P, Tufveson G 


Implementation of a Protocol for ABO-Incompatible Kidney Transplantation - A Three-Center Experience With 60 Consecutive Transplantations
Transplant 2007; 83 (9): 1153-55 
http://www.ncbi.nlm.nih.gov/pubmed/17496528
Genberg H, Kumlien G, Wennberg L. Berg U, Tydén G 


ABO-incompatible kidney transplant using antigen-specific immunoadsorption and rituximab: a 3-year follow-up
Transplantation 2008; 85 (12): 1745-54
http://www.ncbi.nlm.nih.gov/pubmed/18580466
Tydén G, Kumlien G, Berg B


M; Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis
Nephrol Dial Transplant 2010; 25 (11): 3778-86
http://www.ncbi.nlm.nih.gov/pubmed/20466677
Tydén G, Kumlien G, Berg B

Liver

Saliba F, Ichaï P, Azoulay D, Habbouchi H, Antonini T, Sebagh M, Adam R, Castaing D, Samuel D
Successful Long-Term Outcome of ABO-incompatible Liver Transplantation Using Antigen-Specific Immunoadsorption Columns
Therapeutic Apheresis and Dialysis 2010; 14 (1): 116-123 
http://www.ncbi.nlm.nih.gov/pubmed/20438529
Markiewicz-Kijewska M, Kaliciński P, Teisseyre J, Ismail H, Ostoja-Chyzyńska A, Prokurat S, Sokolnicka In 


Liver Transplant with ABO incompatible graft under immunoadsorption protocol - case report
Ann Transplant. 2010: 15 (4): 68-71 
http://www.ncbi.nlm.nih.gov/pubmed/21183879
Troisi R, Noens L, Montalti R, Ricciardi S, Philippe J, Praet M, Conoscitore P, Centers M, Hemptinne B


ABO mismatch adult living donor liver transplant using antigen-specific immunoadsorption and quadruple immunosuppression without splenectomy
Liver Transpl. 2006; 12 (9): 1412-7
http://www.ncbi.nlm.nih.gov/pubmed/16528717

Lung

Strüber M, Warnecke G, Hafer C, Goudeva L, Fegbeutel C, Fischer S, Gottlieb J, Avsar M, Simon AR, Haverich A
Intentional ABO-incompatible lung transplant
Am J Transplant. 2008: 8 (11): 2476-8 
http://www.ncbi.nlm.nih.gov/pubmed/18808407

Heart

Bucin D, Johansson S, Malm T, Jögi P, Johansson J, Westrin P Lindberg LO, Olsson AK, Gelberg J, Perez V, Harling S Benn Hagen R Kornhall B, Ekmehag B, Kurkus J, Otto G 
Heart transplantation across antibodies against human leukocyte antigen and ABO post-transplant follow-up or donor reactive antibodies
Transplant International 2006; 19 (3): 239-244 
http://www.ncbi.nlm.nih.gov/pubmed/16441774


Specific removal of blood group antibodies
  • Glycosorb®-ABO specifically binds blood group antibodies and specifically eliminates these antibodies¹

  • Does not affect other antibodies, coagulation factors or other components in the blood2

High security
  • No need for replacement fluids (blood plasma or chemical solutions)

  • Specific treatment, minor impact on patient total antibody levels, coagulation proteins and other plasma proteins, even when treating multiple plasma

  • Reduces the risk of infections, bleeding and other side effects compared to alternative non-specific methods

Effective treatment
  • Repeatedly shown to effectively lower the levels of blood group antibodies (anti-A / B antibody titer, RBC)

  • For example, repeated titrations of titers from 1: 256 to 1: 8 have been shown after treatment

  • The anti-A / B antibody titre (RBC) has been shown to be 1: 0 or 1: 1 in plasma immediately after the column, even at high levels (anti-A / B titer ≥1: 256) before the column

Continuous improvement of product
  • Glycosorb®-ABO is today a proven medical device

  • The product is significantly more effective today than it was introduced, which allows for fewer treatments per patient

Blood-group-compatible kidney transplants from living donors
  • Reported long-term results (renal function, renal survival and patient survival) equivalent to blood-group-compatible kidney transplants (living donors)

  • The same risk of rejection as for blood-group-compatible kidney transplants (living donors)

  • Transplantation of both adults and children shows beneficial results.

Blood group-compatible liver, cardiac and lung transplants
  • Glycosorb®-ABO has been used to effectively lower the levels of anti-A / B antibodies in acute cases when the levels of anti-A / B antibodies dramatically increased after transplantation and thus prevented acute rejection.

  • Blood group-compatible liver transplants from deceased donors using Glycosorb®-ABO have become a standard at some centers

Stem Cell transplants
  • Glycosorb®-ABO has been successfully used in blood group-compatible stem cell transplants

  • Prevents, for example, hemolysis and anemia and avoids multiple transfusions

¹ It should be noted that Glycosorb®-ABO reduces anti-A / B antibodies belonging to the various subclasses of IgG (IgG1, IgG2, IgG3 and IgG4) and also associated with IgM. However, to a significant extent, the total amount of antibodies is not affected because anti-A / B antibodies represent only a small part of the total amount of antibodies. This has been repeatedly shown on many different plasmids. This distinguishes Glycosorb® ABO from other columns that are selective (protein, peptide or antibody-based columns), which are otherwise normally used for reduction of the total antibody amount in the patient in, for example, autoimmune conditions. These latter columns reduce total IgG1, total IgG2 and total IgG4, but do not significantly reduce total IgG3 or total IgM. In addition to these later colonies, hypogammaglobulinemia causes the patient to achieve significant reduction of anti-A / B antibodies prior to (and / or after) the transplant, the result is that anti-A / B IgG3 and anti-A / B IgM remain in patient even after extensive treatment with these columns. Both anti-A / B IgG3 and anti-A / B IgM can cause rejection in blood group-compatible transplantation (see, for example, Takahashi, ABO-incompatible transplant, Elsevier).